Southwest Securities Initiates Coverage on GenFleet Therapeutics, Recommends Active Attention Due to Global Leadership in Product Pipeline

Deep News05-17

Southwest Securities has issued a research report stating that GenFleet Therapeutics (02595) is targeting major therapeutic areas such as pancreatic cancer, non-small cell lung cancer, and cachexia with its product portfolio, aiming to cover first-line and various subsequent lines of treatment. The company's product development progress is considered globally leading. The report forecasts revenues for 2026-2028 to be approximately RMB 0.85 billion, RMB 1.02 billion, and RMB 3.11 billion, representing year-on-year changes of -35%, +20%, and +205%, respectively. This marks the initiation of coverage on the stock, with a recommendation for active investor attention.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment